TD Cowen Reiterates “Buy” Rating on Vaxcyte (PCVX) With $50 PT

MSN
2025.11.11 01:28
portai
I'm PortAI, I can summarize articles.

TD Cowen analyst Tara Bancroft has reiterated a "Buy" rating on Vaxcyte, Inc. (NASDAQ:PCVX) with a price target of $50. The company is noted for its significant upside potential and hedge fund interest, making it one of the 15 stocks expected to perform well in 2026. This announcement follows positive Phase II data for the company.

Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer